T2 Biosystems (NASDAQ:TTOO) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

Equities research analysts at StockNews.com began coverage on shares of T2 Biosystems (NASDAQ:TTOO – Get Free Report) in a note issued to investors on Monday. The firm set a “sell” rating on the medical equipment provider’s stock.

Separately, Canaccord Genuity Group upped their price objective on shares of T2 Biosystems from $3.00 to $5.00 and gave the company a “hold” rating in a report on Tuesday, July 30th.

Read Our Latest Analysis on TTOO

T2 Biosystems Stock Performance

T2 Biosystems stock traded down $0.02 during trading hours on Monday, reaching $0.49. The stock had a trading volume of 1,257,995 shares, compared to its average volume of 354,126. The business’s 50 day moving average price is $1.27 and its 200-day moving average price is $3.37. T2 Biosystems has a 52 week low of $0.42 and a 52 week high of $8.38.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in T2 Biosystems stock. Virtu Financial LLC boosted its stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO – Free Report) by 29.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 13,096 shares of the medical equipment provider’s stock after purchasing an additional 3,018 shares during the period. Virtu Financial LLC owned approximately 0.24% of T2 Biosystems worth $39,000 at the end of the most recent quarter. Institutional investors and hedge funds own 23.18% of the company’s stock.

About T2 Biosystems

(Get Free Report)

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Further Reading